GOLDMAN SACHS GROUP INC - TREVI THERAPEUTICS INC ownership

TREVI THERAPEUTICS INC's ticker is TRVI and the CUSIP is 89532M101. A total of 54 filers reported holding TREVI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of TREVI THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$218,115
+66.5%
73,193
+92.7%
0.00%
Q1 2024$131,010
+308.8%
37,974
+58.8%
0.00%
Q4 2023$32,046
-43.8%
23,915
-8.5%
0.00%
Q3 2023$57,007
-31.9%
26,150
-25.4%
0.00%
Q2 2023$83,77235,0510.00%
Other shareholders
TREVI THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
NEA Management Company, LLC 11,370,376$27,175,1992.07%
Fairmount Funds Management LLC 5,190,360$12,404,9601.75%
VR Adviser, LLC 3,422,397$8,179,5291.31%
Frazier Life Sciences Management, L.P. 6,881,090$16,445,8050.98%
Opaleye Management Inc. 1,701,500$4,066,5850.97%
SILVERARC CAPITAL MANAGEMENT, LLC 885,924$2,117,3580.66%
Rubric Capital Management LP 5,684,420$13,585,7640.58%
Tejara Capital Ltd 180,227$430,7430.21%
PFS Partners, LLC 100,000$239,0000.20%
WealthTrust Axiom LLC 93,500$223,4650.07%
View complete list of TREVI THERAPEUTICS INC shareholders